April Salama, MD, previously interim director of Duke Cancer Institute’s Melanoma disease group, was recently named director.
Since assuming the role as interim director three years ago, Salama has advanced the DCI's Melanoma disease group.
"Dr. Salama continues to expand the breadth of collaborations both within the institution and beyond," said Michael B. Kastan, MD, PhD, executive director, Duke Cancer Institute. "Under her leadership, the melanoma clinical trials program has been recognized as a leading site for patient accrual in a number of landmark melanoma trials. Her appointment signals the great confidence we have in her leadership and ability to continue to lead the program in a permanent capacity."
Salama received her medical degree from the University of North Carolina at Chapel Hill and completed a residency at the University of Chicago Medical Center. Previously, from 2012 to 2015, Salama served as the associate director of Melanoma Clinical Research Program. She is actively involved in many facets of clinical research, serving as PI for many studies with a goal of providing access to cutting-edge therapy for patients. In addition, Salama also focuses on novel combination strategies for the treatment of patients with advanced melanoma.
The author of numerous publications, Salama is also the recipient of multiple awards, including the 2010 ASCO Merit Award, the 2017 NCI Cancer Clinical Investigator Team Leadership Award and the William H. Kane Junior Faculty Teaching Award.
For more information on the Melanoma disease group at Duke Cancer Institute, visit MP.